PDS Biotechnology Corporation
NASDAQ:PDSBBiotechnology
+$0.01 today
- Market cap
- $51.58M
- Beta
- 1.56
- P/E (TTM)
- -1.5
- EPS (TTM)
- -$0.60
Volume 5.25M
Average 1.04M
PDSB Operating Cash Flow
Cash generated by the company's core business operations during the period.
PDS Biotechnology CorporationNASDAQ: PDSB
Operating Cash Flow · Q1 FY2026 · quarter ended Mar 2026
Operating cash flow growth accelerates
Q1 FY2026 operating cash flow of $4.37B (cash outflow) rose 48300.4% year over year, ahead of the +12765.8% change in trailing-twelve-month operating cash flow. Sequentially, it rose 117970.1% from the prior quarter. Over 3 fiscal years it compounded at +925.8% a year.
Context
- Operating cash flow grew in size in 3 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +48300.4% holds above the trailing-twelve-month pace of +12765.8%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Operating Cash Flow history
USD · from the cash flow
- Latest · FY2025
- (27.75B) USD
- Year-over-year change
- -79123.1%
| Period | Period end | Operating Cash Flow | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (27.75B) | -79123.1% |
| FY2024 | 2024-12-31 | (35.03M) | -4.1% |
| FY2023 | 2023-12-31 | (33.64M) | -30.8% |
| FY2022 | 2022-12-31 | (25.71M) | -105.9% |
| FY2021 | 2021-12-31 | (12.49M) | — |
Operating Cash Flow vs competitors
How PDSB compares with its peers on the latest reported figures
- PDSB's LTM Mar 2026 operating cash flow of $4.39B is the largest of the 6 companies compared; the peer median is $26.53M.
- Its year-over-year change of +12765.8% is the highest of 6, against a peer median of -26.2%.
- Over three fiscal years its annual growth of +925.8% compares with a peer median of +12.1%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $4.39B | +12765.8% | +925.8% | — | |
| LTM Mar 2026 | $56.31M | -366.9% | -59.6% | 105.3% | |
OKUROnKure Therapeutics, Inc. | LTM Mar 2026 | $50.76M | -2.7% | +24.4% | — |
| LTM Mar 2026 | $26.53M | +15.6% | +1039.6% | — | |
| LTM Jun 2026 | $22.66M | -26.2% | — | 64.6% | |
| LTM Mar 2026 | $19.17M | -41.4% | -0.2% | — | |
| Peer median (excluding PDSB) | $26.53M | -26.2% | +12.1% | 84.9% | |
Competitors are the stored peer set for PDSB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (16.92M) | (40.85M) | (42.94M) | (37.61M) | (34.5B) |
| Depreciation & Amortization | 5.36K | 86 | 17.36K | 21.11K | 1.55B |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 4.11M | 5.2M | 7.61M | 6.85M | 4.11B |
| Change in Working Capital | 75.82K | 4.47M | (199.28K) | (5.75M) | (382.97K) |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | (105.82K) | (90.12K) | 5.76M | (5.3M) | 1.89M |
| Other Working Capital | 181.64K | 4.57M | (5.96M) | (453.77K) | (2.27M) |
| Other Non-Cash Items | 241.03K | 5.47M | 1.87M | 1.46M | 1.08B |
| Operating Cash Flow | (12.49M) | (25.71M) | (33.64M) | (35.03M) | (27.75B) |
| Capital Expenditures | 0 | 0 | 0 | (29K) | 0 |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | 0 | 0 | 0 | (29K) | 0 |
| Debt Repayment | 0 | 25M | (59.3K) | (3.18M) | (7.56M) |
| Common Stock Issued | 48.54M | 9.86M | 16.13M | 22.6M | 20.34M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 344.13K | (568.87K) | 308.94K | 774.09K | 12.76B |
| Financing Cash Flow | 48.89M | 34.29M | 16.38M | 20.19M | 12.77B |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 36.4M | 8.58M | (17.26M) | (14.87M) | (14.98B) |
| Free Cash Flow | (12.49M) | (25.71M) | (33.64M) | (35.06M) | (27.75B) |
PDS Biotechnology Corporation
NASDAQ:PDSB
Intrinsic Alpha fair value
Locked
Current Price
$0.92
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.